CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD | Market Cap | 66.30B -48.1% |
| Revenue (ttm) | 23.10B +1.2% |
| Net Income | 2.09B -49.2% |
| EPS | 4.29 -49.5% |
| Shares Out | 478.91M |
| PE Ratio | 32.28 |
| Forward PE | 15.50 |
| Dividend | 4.14 (2.99%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 1,130,216 |
| Open | 138.65 |
| Previous Close | 138.44 |
| Day's Range | 136.31 - 138.94 |
| 52-Week Range | 90.00 - 273.45 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 137.05 (-0.34%) |
| Earnings Date | Aug 18, 2026 |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul... [Read more]
Financial Performance
In fiscal year 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CSL stock is "Buy." The 12-month stock price target is $137.05, which is a decrease of -0.34% from the latest price.
News
CSL to start clinical trials for new immunoglobulin manufacturing process
Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same...
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress...
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswi...
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progr...
CSL Limited Transcript: Investor update
A comprehensive review confirmed the need for transformation, with efficiency measures and commercial enhancements underway. FY 2026 guidance was revised lower due to inventory and pricing headwinds, with significant impairments flagged. Leadership remains confident in a return to profitable growth.
CSL Limited Slides: Investor update
CSL Limited has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
CSL Limited Press release: Investor update
CSL Limited issued a press release on May 10, 2026, disclosing material business information to investors.
CSL announces expansion of Illinois plasma therapy manufacturing facility
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies a...
CSL Limited Earnings Call Transcript: H1 2026
First half revenue and profit declined due to policy changes, one-off costs, and impairments, but strong cash flow and cost savings supported an expanded share buyback. Guidance is maintained, with second half growth expected from IG, albumin, and new products, while competitive and regulatory headwinds persist.
CSL Limited Quarterly report: H1 2026
CSL Limited has published its H1 2026 quarterly earnings report on February 10, 2026.
CSL Limited Slides: H1 2026
CSL Limited has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 10, 2026.
CSL Limited Earnings release: H1 2026
CSL Limited released its H1 2026 earnings on February 10, 2026, summarizing the period's financial results.
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is ...
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- ...
CSL Limited Transcript: CMD 2025 Part 2
Management is focused on restoring credibility and driving shareholder returns through operational efficiency, innovation, and disciplined capital allocation. IG remains the core growth driver, with high single-digit growth expected, while new products and cost-saving initiatives support robust, sustainable performance.
CSL Limited Slides: FY 2025
CSL Limited has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 4, 2025.
CSL Limited Transcript: CMD 2025 Part 1
Influenza market complexity enables strategic differentiation, with growth driven by advanced vaccine technologies and a customer-focused approach. U.S. immunization rates are down, but recovery is expected to accelerate growth, especially with new products like aTIVc and international expansion.
CSL Limited Slides: FY 2025
CSL Limited has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 4, 2025.
CSL upgraded to Buy from Hold at Canaccord
Canaccord analyst Shane Storey upgraded CSL (CSLLY) to Buy from Hold with a price target of A$225, down from A$230. The annual general meeting downgrade was primarily related to Seqirus,…
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA , Oct. 26, ...
CSL Limited Transcript: AGM 2025
The AGM reviewed strong FY2025 financial results, announced a $2.92 dividend, and outlined bold cost-saving and simplification initiatives. Board changes, a deferred Seqirus demerger, and a second strike on remuneration were key topics, alongside shareholder concerns on performance, R&D, and communication.
CSL Limited Slides: FY 2025
CSL Limited has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 26, 2025.
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the pr...
CSL Limited Earnings Call Transcript: H2 2025
Group revenue grew 5% and NPAT rose 17% year-over-year, with all business units contributing to growth. Major transformation initiatives, including $500M+ in cost savings and a planned Seqirus demerger, are underway. FY2026 guidance anticipates 4%-5% revenue growth and 7%-10% NPATA growth.